Every 10-Q that MDB Capital Holdings, LLC (MDBH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MDBH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MDBH filings page.
MDB Capital Holdings, LLC operates a broker-dealer and intellectual property services platform, with a majority-owned drug development subsidiary and a large equity stake in eXoZymes. As of June 30, 2026, total assets were $50.8 million, down from $63.7 million at December 31, 2025, largely reflecting declines in investment securities and the equity method investment. Liabilities remained low at $1.3 million, leaving total equity of $49.5 million.
For the quarter ended June 30, 2026, MDB reported a net loss attributable to the company of $9.3 million, and a six‑month net loss of $16.1 million, compared with $14.9 million in the prior‑year period. Results were affected by $4.9 million in unrealized losses on broker‑dealer investment securities, a $3.1 million share of eXoZymes’ losses, and a $1.36 million dilution‑related loss. MDB also recorded a $641 thousand impairment on its equity investment in eXoZymes, reducing the carrying value to $33.1 million.
Operating activities used $5.5 million of cash in the first half of 2026, leaving cash, cash equivalents, and segregated cash of $9.9 million at June 30, 2026. The broker‑dealer subsidiary reported net capital of $8.96 million, well above regulatory minimums, and the company has an undrawn $2.0 million revolving credit facility secured by cash, indicating modest leverage but ongoing cash burn.
MDB Capital Holdings, LLC reported a net loss of 6,736 (in thousands) for the three months ended March 31, 2026, compared with a loss of 6,602 (in thousands) a year earlier. Total operating income was 44 (in thousands), as fee income of 2,862 (in thousands) and other income were largely offset by a 3,047 (in thousands) unrealized loss on investment securities at the licensed broker dealer.
General and administrative costs declined to 5,525 (in thousands) from 6,738 (in thousands), mainly from lower compensation. The equity method investment in eXoZymes generated a loss of 1,108 (in thousands), and its carrying amount was 36,339 (in thousands). Total assets were 57,463 (in thousands), and total equity was 56,224 (in thousands). Cash, cash equivalents and restricted cash totaled 12,534 (in thousands), with net cash used in operating activities of 2,945 (in thousands). As of May 14, 2026, 5,438,632 Class A Common Shares were outstanding.
MDB Capital Holdings, LLC (MDBH) filed its Q3 2025 report, posting a net loss of $4,656,811 for the quarter. Year to date, the company recorded a net loss of $19,508,201. Quarterly results reflected an $1,225,329 unrealized gain on investment securities and $25,563 of other operating income, more than offset by $5,006,159 in general and administrative costs.
Total assets were $61,511,325 at September 30, 2025, down from $71,976,399 at December 31, 2024, with cash and cash equivalents of $15,094,286. For the nine months, fee income was $2,140,238 and the net unrealized loss on investment securities was $2,430,483. The equity method investment in eXoZymes carried a balance of $38,735,148 after recognizing losses of $1,068,539 in Q3 and $3,048,283 year to date. Basic and diluted net loss per Class A share was $(0.46) in Q3 and $(1.95) year to date. As of November 13, 2025, Class A shares outstanding were 5,138,632. The company’s $2,000,000 revolving credit facility had no outstanding borrowings.